Clinical Trials

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02609776 2026-05-08

CHRYSALIS

751 enrolled 1 FDA

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-05-08

Chrysalis-2

701 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-05-08

PAPILLON

308 enrolled 12 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05074940 2026-05-08

Amivantamab in Adenoid Cystic Carcinoma

21 enrolled 13 charts

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05379595 2026-05-08

OrigAMI-1

Phase 1/2 Recruiting

225 enrolled

Colorectal Neoplasms

NCT05388669 2026-05-08

PALOMA-3

418 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT05488314 2026-05-08

METalmark

57 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-05-08

PALOMA-2

520 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-05-08

COCOON

305 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06385080 2026-05-08

OrigAMI-4

Phase 1/2 Recruiting

287 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06662786 2026-05-08

OrigAMI-2

Phase 3 Recruiting

1,000 enrolled

Colorectal Neoplasms

NCT06667076 2026-05-08

COPERNICUS

480 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06750094 2026-05-08

OrigAMI-3

Phase 3 Recruiting

700 enrolled

Colorectal Neoplasms

NCT07227025 2026-05-08

KaRAnaSa

Phase 1/2 Recruiting

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07276399 2026-05-08

OrigAMI-5

Phase 3 Recruiting

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06116682 2026-05-06

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

88 enrolled

Other solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung

NCT06816992 2026-04-24

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Phase 1 Recruiting

76 enrolled

Solid Tumors

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06532032 2026-04-13

swalloWTail

12 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05801029 2026-03-20

OSTARA

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-03-13

PolyDamas

71 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

197 enrolled

Colorectal Neoplasms

NCT06083857 2026-03-11

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

3 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05117931 2026-02-17

A Study of Amivantamab in People With Esophagogastric Cancer

25 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06507306 2026-02-06

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Phase 1 Recruiting

100 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT07392658 2026-02-06

AMICUTE

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05845671 2026-01-14

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

12 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

43 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05299125 2025-10-01

AMIGO-1

54 enrolled

Phase 2 Not yet recruiting

Metastatic Non-small Cell Lung Cancers

NCT06632236 2025-04-25

5G-EMERALD

Phase 1 Recruiting

12 enrolled

CNS

Glioblastoma

NCT06855849 2025-03-04

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

85 enrolled

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients

NCT05653427 2025-01-13

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Phase 2 Terminated

18 enrolled 20 charts

Carcinoma, Hepatocellular

NCT04945733 2024-09-19

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Phase 2 Terminated

62 enrolled 28 charts

Esophageal Neoplasms, Stomach Neoplasms

NCT03767075 2024-04-25

BoB